BDH Industries Ltd.
Snapshot View

123.50 +1.65 ▲1.4%

20 May 2022, 04:01:00 PM
Volume: 5,891

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.bdhind.com
Market Cap 71.10 Cr.
Enterprise Value(EV) 55.80 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 12.49 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 9.89 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 78.73 Trailing Twelve Months Ending 2021-12
Price to Book Value 1.57 Calculated using Price: 123.50
Dividend Yield 2.43 Period Ending 2021-03
No. of Shares Subscribed 0.58 Cr. 5,757,300 Shares
FaceValue 10
Company Profile

BDH Industries was incorporated on December 5, 1990 and was converted into a public limited company on April 29, 1994.

BDH Industries is engaged in the manufacture and marketing of formulations and bulk drugs. It is today recognised as one of India's leading manufacturers of therapeutic formulations covering wide range of pharmaceuticals.

BDH exports a wide range of finished pharmaceutical formulations and bulk drugs to leading organizations in several countries, including Australia, Bolivia, Denmark, Dominican Republic, Germany, Ghana, Japan, Kenya, Madagascar, Malaysia, Mozambique, Netherlands, Niger, Nigeria, Papua New Guinea, Yemen, Singapore, Sri Lanka, Sudan, West Indies, Zambia, Zimbabwe, etc.

Products offered by the Company:

Some of its therapeutical categories are:

1. Anti-cancer 2. Antibiotics & Anti-microbials 3. Cardiovascular 4. Psychotropic 5. External Preparations 6. Sterile Opthalmics Preparations 7. Generics & Branded Generics 8. Injectables

It also manufactures sildenafil citrate tablets for male impotency

Achievements:

  • The Government of the India has accorded 'Star Export House' status to the company
  • The Government of India also accredited the company with WHO-GMP Certification since 1982.
  • It has received Federation of Indian Export Organisations (FIEO) Export Award 'Niryat Shree'
  • The company has received Chemexcil Top Export Award
  • It has also received Chemexcil Trishul Award for Consistent Export Performance
  • It has received the Government of Maharashtra's Export Award
  • Ministry of Commerce's Award from the President of India was conferred on the company.
  • 2010
    • BDH Industries won ‘Good Corporate Citizen’ Award by Bombay Chamber of Commerce & Industry 2010
    • BDH Industries won State Pharmaceutical Corporation (SPC) Sri Lanka Merit Award 2010
    • WHO-GMP Certificatation since 1982, renewed WHO-GMP in 2010

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.35%
1 Week
+1.23%
1 Month
-13.33%
3 Month
-12.69%
6 Month
+0.98%
1 Year
+26.47%
2 Year
+108.79%
5 Year
+47.11%
10 Year
+671.88%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 8.49 11.02 11.69 13.40 12.51 13.13 15.46 17.11 16.26
Return on Capital Employed (%) 12.36 13.55 13.25 15.39 14.90 14.74 16.94 19.14 18.74
Return on Assets (%) 4.39 5.11 5.15 6.23 6.27 6.77 7.88 9.08 9.35

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 22 23 24 27 29 31 34 38 43 45
Non Curr. Liab. 1 1 1 1 2 2 1 1 1 1
Curr. Liab. 19 24 27 24 23 24 30 26 27 25
Minority Int.
Equity & Liab. 42 48 52 52 54 57 66 65 71 70
Non Curr. Assets 15 15 13 17 23 23 22 21 20 20
Curr. Assets 27 33 38 35 31 34 44 44 51 50
Misc. Exp. not W/O
Total Assets 42 48 52 52 54 57 66 65 71 70

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 41 43 45 46 44 41 52 59 57 71
Other Income 1 1 1 2 1 1 1 1 1 1
Total Income 41 44 46 48 45 42 53 60 59 72
Total Expenditure -37 -39 -41 -42 -39 -36 -45 -51 -49 -61
PBIDT 4 5 5 6 6 6 8 10 10 11
Interest -1 -1 0 0 0 0 -1 -1 0 0
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
Taxation -1 -1 -1 -2 -2 -1 -2 -2 -2 -3
Exceptional Items
PAT 2 2 3 3 3 4 5 6 6 7
Adjusted EPS 3 4 4 6 6 7 8 10 11 12

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 9 5 4 6 4 7 0 -4 11 1
Cash Fr. Inv. 0 -1 0 0 -5 -5 0 1 1 1
Cash Fr. Finan. -3 1 3 -3 -1 -3 -3 3 -6 -2
Net Change 5 6 6 3 -1 -1 -2 0 6 0
Cash & Cash Eqvt 6 12 18 21 20 19 17 17 23 23

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 55.56 55.56 55.56 49.79 49.79 49.73 49.66 49.66 49.66
Public 44.44 44.44 44.44 50.21 50.21 50.27 50.34 50.34 50.34
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 18 May 2022
Board Meeting Intimation for Considering And Approving The Audited Standalone Financial Results For The Fourth Quarter And Financial Year Ended On 31St March 2022 And Recommendation Of Dividend If Any For The Financial Year Ended On 31St March 2022.
BDH INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 inter alia to consider and approve the Audited Standalone Financial Results for the fourth quarter and financial year ended on 31st March 2022 and Recommendation of dividend if any for the financial year ended on 31st March 2022.
Wed, 27 Apr 2022
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayBDH INDUSTRIES LTD.
2CINL24100MH1990PLC059299
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Ms NIKITA PHATAK
Designation: COMPANY SECRETARY
EmailId: comp.sec@bdhind.com
Name of the Chief Financial Officer: Mr S C KACHHARA
Designation: CHIEF FINANCIAL OFFICER
EmailId: info@bdhind.com

Date: 27/04/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Sat, 16 Apr 2022
Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
Certificate under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 is enclosed herewith.

Technical Scans View Details

Fri, 20 May 2022
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%